Yousif Capital Management LLC Trims Stock Position in Edwards Lifesciences Corporation $EW

Yousif Capital Management LLC lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,743 shares of the medical research company’s stock after selling 1,890 shares during the period. Yousif Capital Management LLC’s holdings in Edwards Lifesciences were worth $6,706,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. Pacific Capital Partners Ltd purchased a new position in shares of Edwards Lifesciences during the second quarter worth $1,760,000. Czech National Bank raised its holdings in shares of Edwards Lifesciences by 5.8% during the second quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock worth $11,214,000 after purchasing an additional 7,917 shares during the last quarter. Dynamic Advisor Solutions LLC raised its holdings in shares of Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock worth $1,124,000 after purchasing an additional 370 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock worth $5,582,000 after purchasing an additional 9,188 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on EW. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Mizuho lifted their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Finally, Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $87.06.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Up 0.6%

Shares of NYSE EW opened at $73.39 on Wednesday. The company’s 50-day simple moving average is $77.83 and its 200-day simple moving average is $76.16. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $83.00. The firm has a market cap of $43.09 billion, a price-to-earnings ratio of 10.56, a price-to-earnings-growth ratio of 3.50 and a beta of 1.05. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the business earned $0.70 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.